← Oncology Approval Tracker

FDA DECISION ·

Retevmo

selpercatinib · Eli Lilly

Accelerated approvalNew or expanded indicationTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Jul 14, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic RET fusion-positive solid tumors progressing on or after prior systemic treatment or without satisfactory alternatives.

LAMPGEN ANALYSIS

Why it matters

The action extends RET-directed treatment beyond lung and thyroid cancer to a molecularly selected solid tumor population.

What research teams should watch

Verify a RET fusion, tumor extent, and therapy history rather than relying on a generic RET alteration field.

PRIMARY RECORDS

Sources